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Abstract
The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing
disease-causing sequence variants from the many potentially functional variants present in any
human genome are urgently needed. Without rigorous standards we risk an acceleration of false-
positive reports of causality, which would impede the translation of genomic research findings
into the clinical diagnostic setting and hinder biological understanding of disease. Here we discuss
the key challenges of assessing sequence variants in human disease, integrating both gene-level
and variant-level support for causality. We propose guidelines for summarizing confidence in
variant pathogenicity and highlight several areas that require further resource development.
High-throughput sequencing approaches can generate detailed catalogues of genetic
variation in both disease patients and the general population. However, for these
technologies to have the greatest medical impact we must be able to separate genuine
disease-causing or disease-associated genetic variants reliably from the broader background
of variants present in all human genomes that are rare, potentially functional but not actually
pathogenic (Box 1) for the disease or phenotype under investigation.
Many, but unfortunately not all, variants that have been causally associated with rare and
common genetic disorders represent robust and correct conclusions. False assignments of
pathogenicity can have severe consequences for patients, resulting in incorrect prognostic,
therapeutic or reproductive advice, and for the research enterprise, resulting in misallocation
of resources for basic and therapeutic research. Unfortunately, although the vast majority of
genes reported as causally linked to monogenic diseases are true positives, false assignments
of causality at the variant level are a substantial issue. One recent analysis of 406 published
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tsevere disease mutations observed in 104 newly sequenced individuals reported that 122
(27%) of these were either common polymorphisms or lacked direct evidence for
pathogenicity1. Other studies have identified numerous alleged severe-disease-causing
variants in the genomes of population controls2,3. In other cases, well-powered follow-up
studies of high-profile reported mutations have cast serious doubts on initial reports
assigning disease causality to sequence variants4,5, but the vast majority of false-positive
findings probably remain undetected. As the volume of patient sequencing data increases it
is critical that candidate variants are subjected to rigorous evaluation to prevent further mis-
annotation of the pathogenicity of variants in public databases.
This paper describes the challenges in reliably investigating the role of sequence variants in
human disease, and approaches to evaluate the evidence supporting variant causality. It
represents the conclusions of a working group of experts in genomic research, analysis and
clinical diagnostic sequencing convened by the US National Human Genome Research
Institute.
We focus on the application of genome-scale approaches to investigating rare germline
variants, defined here as variants with a minor allele frequency of <1%. Our
recommendations are most relevant for variants with relatively large effects on disease risk.
Our intended scope encompasses the vast majority of variants implicated in severe
monogenic diseases as well as rare, large-effect risk variants in complex disease6, but
excludes the common, small-effect variants typically identified by genome-wide association
studies of complex traits7.
Unambiguous assignment of disease causality for sequence variants is often impossible,
particularly for the very low-frequency variants underlying many cases of rare, severe
diseases. Consequently, we refer in this manuscript to the concept of implicating a gene or
sequence variant: that is, the process of integrating and assessing the evidence supporting a
role for that gene or variant in pathogenesis. We emphasize the primacy of strong genetic
support for causation for any new gene, which may then be supplemented and extended with
ancillary support from functional and informatic studies.
Our recommendations centre on five key areas: study design; gene-level implication;
variant-level implication; publication and databases; and implications for clinical diagnosis.
Core guidelines for researchers are summarized in Box 2. We also provide a list of factors to
consider in the analyses of candidate variants in presumed monogenic diseases
(Supplementary Information) and a list of resources for assessing pathogenicity
(Supplementary Table 1).
Study design
Investigators seeking to identify pathogenic variants should select technological and
analytical approaches based on the most likely genetic architecture of the disease of interest.
Rare, high-penetrance protein-coding variants can be cost-effectively captured by exome
sequencing, which is rapidly becoming the first-line approach for presumed monogenic
disorders8. Cytogenomic arrays and genotyping of linkage panels remain useful approaches
for the identification of copy number variation and for identifying co-segregating haplotypes
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twithin large Mendelian (especially dominant) disease families, respectively. Optimal
approaches to discovering rare pathogenic variants in complex diseases remain unclear:
exome sequencing9, deep and low-coverage whole-genome sequencing10 and/or next-
generation genotyping arrays with enhanced coverage of protein-coding variants are all
being applied in research settings. As the cost of sequencing declines, we expect that deep
whole-genome sequencing will soon become the technology of choice for investigating all
genetic architectures.
In selecting technological and analytical approaches for a new study, investigators should
consider formal power calculations11 incorporating predicted distributions of allele
frequencies and effect sizes for pathogenic variants, genetic and phenotypic heterogeneity of
available cohorts, population frequency of the disease, and available sample sizes. Although
parameter values may be uncertain, current knowledge of the genetics of the disease and
similar traits can be used to constrain likely ranges. In particular, for many diseases there is
overwhelming evidence that both locus and allelic heterogeneity is high, such as autism,
epilepsy and schizophrenia. A study design that assumes low locus and allelic heterogeneity
would be certain to fail for these conditions, and this fact would be revealed by even casual
evaluations of power for reasonable genetic models. Gene discovery for conditions with low
locus heterogeneity and sufficiently high-penetrance mutations is occasionally possible by
sequencing a single family12, however most gene-discovery applications will require
substantially larger sample sizes: multiple unrelated families for rare monogenic conditions,
and thousands to tens of thousands of patients and controls for complex disorders9,13.
To assemble large sample sizes will typically require pooling of patient cohorts by multiple
investigators. Although such consortium approaches are desirable, investigators should be
mindful of systematic differences among cohorts stemming from technical biases,
population stratification, and genetic and phenotype heterogeneity. For studies of complex
traits, many quality-control methods developed for genome-wide association studies of
common variants will also apply to rare variant studies14, but DNA sequencing data face a
different and typically more challenging set of quality considerations, particularly when data
sets are combined for meta-analysis. In addition, new methods may need to be developed to
address population stratification of rare variants15, which show stronger geographic
clustering than common variants16; to minimize the impact of stratification, controls should
be matched closely to the ancestry of patient samples.
For presumed monogenic diseases, the availability of multiple families with very similar
clinical phenotypes substantially increases power for gene discovery. For cases in which
there is a single affected proband and no family history, investigators should consider
sequencing the unaffected parents of the probands, permitting efficient discovery of de novo
mutations and compound heterozygous genotypes. Investigators should begin by examining
sequence variation in genes known to be associated with that phenotype, and assessing
sequence coverage of the coding sequences and splice junctions for these genes before
exploring the possibility of new candidate genes in the affected individuals.
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To implicate a variant as pathogenic requires that the DNA sequence affected by that variant
has a role in the disease process. For genes not previously reported as causal, investigators
must simultaneously demonstrate evidence for a role of a candidate gene and one or more
variants disrupting it. Even if the candidate gene has been previously implicated in the same
or a similar disease phenotype, the overall support from published sources should be
carefully assessed and reported. Multiple classes of evidence may potentially contribute to
pathogenic inferences at the level of both gene and variant, and include genetic, informatic
and experimental data (Table 1 and Supplementary Information). However, in keeping with
the history of the field of human genetics, we emphasize the critical primacy of robust
statistical genetic support for the implication of new genes, which may then be
supplemented with ancillary experimental or informatic evidence supporting a mechanistic
role for the gene in the disease in question.
Historically, gene-level implication in monogenic diseases has relied first on identifying a
narrow set of candidate genes through genetic data such as linkage analyses or experimental
data on biochemical function, and then identifying rare, probably damaging variants
(altering the normal levels or biochemical function of a gene or gene product) in one of the
candidate genes in multiple affected patients. The increasing availability of large-scale
sequencing data now allows genome-scale approaches to gene discovery, in which the
distribution of rare, predicted gene-disrupting variants in patients is systematically compared
to population controls or well-validated null models to identify genes with an excess of
potentially pathogenic variants for clinical and functional follow-up.
It is worth emphasizing that the whole-genome sequence data sets are in some ways more
prone to misinterpretation than earlier analyses because of the sheer wealth of candidate
causal mutations in any human genome, many of which may provide a compelling story
about how the variant may influence the trait; a problem that has been referred to as the
‘narrative potential’ of human genomes17. To avoid such biases the evidence supporting any
candidate gene should be contrasted wherever possible with the evidence observed at other
presumably non-disease-related genes (for example, by ranking the gene among all others
and reporting the probability of a similar or greater contrast being observed by chance).
Formal genome-wide statistical approaches to monogenic-disease gene discovery will
require considerable methods development, but general guidelines for establishing the
significance of variation can be considered here. As we discuss below, these considerations
apply equally to assessing the significance of rare variation in common disease studies.
Our paramount recommendation is that for genome-wide analyses of rare variants for both
Mendelian and complex disorders, formal calculation of statistical significance should be
used to evaluate the strength of evidence of a set of findings, following the well-established
standard of maintaining overall type I (false discovery) error rates below 5%. For example,
investigators should not simply assume that the presence of two or more independently
occurring de novo mutations in the same gene within a sequenced cohort is definitive
evidence of a causal role for that gene18,19; such a threshold results in ever increasing
numbers of false positives as the number of sequenced cases increases. To illustrate this,
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tconsider the recent situation of four exome sequencing studies, involving a total of 945
families with a child affected by autism20–23, which together observed four independent de
novo missense mutations in TTN. Nevertheless, the investigators did not consider TTN to
have a causal role in autism, and appropriately so: using a statistical model similar to
previously published approaches6,22,24 that accounts for gene size (TTN has the largest
coding sequence of any gene in the genome), mutation rate, number of trios and distribution
of exome coverage, 1.96 de novo TTN missense or loss-of-function mutations are predicted
by chance, which is not significantly different (P = 0.14) from the four observed.
We consider a single gene as the fundamental unit for monogenic disease gene testing, for
all disease models; a disease caused by de novo mutations or a disease caused by inherited
dominant or recessive variants. An appropriate framework for detecting pathogenic variants
will evaluate all of the variation in a gene compared to a well-calibrated null model specific
for the hypothesis being considered (for example, de novo, dominant, recessive).
Although the field has well-established guidelines for declaring significance using linkage
data25, it is now important to consider a conservative baseline threshold for declaring
significance purely from sequencing data of cases, in the absence of other genealogical
information. In this scenario, as the gene is the fundamental unit of analysis, and there is no
additional data to constrain the search space for genes, a typical study might perform tests
on 21,000 protein-coding genes and 9,000 long non-coding RNA genes26,27. A conservative
genome-wide significance threshold corresponding to this testing strategy is a Bonferroni-
corrected P value of 1.7 × 10−6 (that is, 0.05 out of 30,000). Importantly, if several different
schemes are used to define ‘qualifying mutations’ in such analyses, it is necessary to make
further statistical adjustments for each of the different sets of rules that are employed.
Formal null models can be specified based on the disease model of interest. As mentioned
above, the null model for the case of the de novo mutation analysis should consider
confounding variables such as sample size, gene size, and mutation rate (which may vary by
orders of magnitude among genes). We note that such null models have power even for
extremely rare conditions and small sample sizes: the first exome sequencing study of
Kabuki syndrome28 initially identified 7 de novo loss-of-function variants in the MLL2 gene
in just 10 sequenced patients, a finding that is extremely unlikely by chance under the
background mutation model described above (P = 1.9 × 10−28) and that provided compelling
evidence implicating this gene as causal.
Formal methods for assessing the significance of observations in rare disease cohorts can
also be used to assess, for example, the aggregate evidence for segregation of rare variants in
a particular gene when considering inherited variation, building on previously published
examples29. In this case, the null model should be a population genetic model, for instance,
the site frequency spectrum (SFS) of variation constructed from a well-matched control
cohort. The null model of the SFS for a given gene should consider both the mutation rate
and selective constraint acting on that gene. When evaluating data from a single case, the
probability that the variation in a gene is from the null model can by estimated by first
identifying the most pathogenic class of variant present in that gene in that case, and then by
calculating the probability of sampling a variant of the same class of pathogenicity from the
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tnull SFS. Similarly, when the recessive disease model applies, the most pathogenic class of
variant on the paternal and maternal haplotypes is identified, and then the probability of
sampling both variants from the null SFS is calculated. This testing framework for inherited
variants is easily scaled to include multiple disease cases. Ideally, to avoid false positives,
the control cohort upon which the SFS is based would be sequenced and analysed in a
manner identical to the disease cases.
Such methods may not yet be applicable to every rare disease scenario, and will require
work to extend to more exotic inheritance modes such as parental imprinting or obligate
compound heterozygosity30. Although formal methods are established to perform these tests
rigorously, researchers should at the very least evaluate and report the level of background
variation in an implicated gene in population cohorts, taking advantage of public resources
such as the Exome Variant Server (http://evs.gs.washington.edu/EVS/) when implicating a
new gene in pathogenesis. Furthermore, the analysis of at least some number of controls,
sequenced and analysed in a manner identical to cases, can be critical for avoiding the
systematic false positives that remain commonplace in exome and genome sequencing.
Just as for genome-wide association studies of common variants14, replication of newly-
implicated disease genes in independent families or population cohorts is critical supporting
evidence, and in most cases essential for a novel gene to be regarded as convincingly
implicated in disease. For the rarest disorders additional cases for independent replication
may be unavailable and it may be impossible to make a compelling statistical case for
implication from human genetic data alone. In these cases, gene implication must be based
on an integrated analysis of genetic, informatic and experimental evidence.
Provided that it is carried out in a statistically rigorous fashion, ancillary information can be
used to boost power for gene discovery. For example, many genome-wide sequencing-based
studies treat all protein-altering variants equally while ignoring all other classes of variants.
More elegant schemes aimed at prioritizing based on predicted pathogenicity may boost
power for such studies. Another approach is to stratify gene candidates by their expression
in a tissue appropriate to the disease under analysis. For example, a recent study combined
variant- and gene-level stratification to show that the de novo mutation rate in congenital
heart disease was similar in cases versus controls, but the odds ratio rose to 7.5 when
focusing on de novo mutations predicted to be damaging and to occur in genes expressed in
the developing heart31.
Experimental evidence that can contribute to support for gene implication falls into three
broad categories, listed here in order of increasing strength. First, experimental data can be
used to demonstrate that the normal function of the gene is consistent with the known
biology of the disease process, for example by showing that the gene is expressed in tissues
relevant to the disease32, or that its protein product co-localizes with, or physically interacts
with, the products of other genes previously implicated in the disease33. Second,
investigators can demonstrate that a gene product is functionally disrupted by mutations in
patients with the disease of interest, as discussed in the variant-level evidence section below.
Lastly, disruption of the candidate gene in a model organism can be shown to result in a
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tphenotype that recapitulates the relevant pathology in humans and is unlikely to occur with
disruption of genes selected at random34,35.
A complete description of the experimental methods relevant to gene implication falls
outside the scope of this manuscript. However, we note that the value of experimental
approaches depends critically on the appropriateness of the model system to the human
disorder that is being investigated. Whether cell line or animal models will be most
appropriate will depend on context: simple cultured cell models may be inappropriate for
developmental disorders affecting complex organ systems. For similar reasons, animal
models are not well suited for analysis of human-specific aspects of biology.
As noted above, it is also important to consider the specificity of gene-level support; that is,
the probability of observing a similar result if the experiment or analysis was performed
with a randomly selected gene. For example, if a new candidate gene is implicated in non-
syndromic short stature in humans, observing that its orthologue is associated with small
body size in knockout mice is relatively uninformative given that a similar phenotype occurs
in over 30% of all knockout mouse strains36. Similarly, reports that the product of a gene
potentially implicated in a metabolic disorder is localized to mitochondria should also
consider that these are complex organelles with many highly expressed genes. [Wherever
possible, investigators should use informatics approaches to assess such metrics in publicly
available high-throughput data sets of functional genomic and model organism phenotype
data37. Although it remains challenging to quantify the statistical confidence of functional
observations, those that can be convincingly demonstrated to represent very low-probability
events under an appropriate null hypothesis provide more compelling support for
implicating a given variant. Even in situations in which a formal statistical framework is not
possible we emphasize that researchers must assess functional data rigorously and clearly
report their limitations.
Variant-level implication
Genetic evidence implicating a variant must be assessed within the context of the
considerable background of rare genetic variants in humans. Even healthy individuals carry
many rare protein-disrupting variants38, and about half carry at least one de novo protein-
altering mutation39. Such variants are therefore not typically sufficient proof of causality
when observed in a disease case, even if present in well-established disease genes: genes
differ markedly in their tolerance to variation40 and rare variants predicted to be damaging
in disease-associated genes are often observed even in population controls41.
In both established and newly implicated disease genes, investigators should formally assess
and report the statistical support for association. Family-based studies should also assess co-
segregation of candidate variants with disease status. Given that a separate, unobserved
pathogenic mutation may lie on the same haplotype as the candidate variant, segregation
analysis alone cannot definitively implicate a specific variant as pathogenic, but (at least
under an assumption of complete penetrance) lack of segregation can exclude non-
pathogenic variants from consideration.
MacArthur et al. Page 8
Nature. Author manuscript; available in PMC 2014 October 24.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tInformatic and/or experimental evidence for variant implication can be used to assess
whether a variant is likely to be deleterious in an evolutionary sense (Box 1), which
primarily comes from in silico annotation and comparative genomics42, and predict that a
variant is damaging in terms of biological function, arising both from computational
predictions and experimental assays. Both categories of evidence can support implication,
but they do not necessarily demonstrate a causal role for the variant with respect to the trait
under study. Again, we stress that hundreds to thousands of coding variants in an individual
will typically be labelled as potentially deleterious or damaging, or both; the strength of the
resulting evidence for pathogenicity must be considered in the context of this background
level of variation.
Measures of evolutionary sequence conservation are widely used indicators of
deleteriousness for both protein-coding and non-coding variation42. Such approaches have
demonstrated value in prioritizing candidate variants43,44; however, their predictive power is
limited by both statistical and biological factors. Many deleterious variants do not show a
strong conservation signature, particularly if the gene has been subject to rapid evolution in
the human or primate lineage, or if there have been compensatory substitutions in other
regions of the protein in ancestral species45. Conversely, strong conservation can be
maintained at sites subject to even relatively weak selective pressure, at which variants may
have only small effects on disease risk. The power of these methods also depends on the
accuracy and phylogenetic scope of the underlying sequence alignments. These limitations
should be taken into account when using predictions of deleteriousness as evidence for
implication. Even though it is worthwhile to employ multiple prediction algorithms,
investigators should avoid treating these as though they represent strong or independent
lines of evidence for pathogenicity.
Although some classes of variation, such as truncating or splice-site-disrupting variants in
the middle of a protein-coding gene, are more likely to be damaging than others, such
variants are also enriched for sequencing and annotation errors and may be rescued by
alternative RNA splicing, other variants, or local sequence context41. These possibilities
should be assessed, and if possible the predicted damaging effect should be confirmed
experimentally.
Experimental approaches to investigating the impact of a sequence variant on gene function,
or cell or organism phenotype, can also have a role in demonstrating that a variant is
damaging to gene function and in identifying the molecular mechanisms underlying a
variant’s effect on disease risk. However, great care must be taken to select appropriate
experimental methods, which will depend on the class of variant, biological context (for
example, tissue type), access to samples and reagents, desired throughput, time and cost.
When a gene has already been confidently implicated in disease, and it is known what class
of variant is causal (for instance, loss or gain of function as represented by a specific assay),
then an experiment that places a variant of unknown significance into such a functional class
can be particularly informative.
Evidence derived directly from patient tissue or cells can often be stronger than that from
model systems, particularly (for loss-of-function variants) if the molecular defect can be
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trescued by complementation in a cellular assay. Replicating disease-relevant phenotypes in
a heterologous cell line engineered to carry the proposed causal variant can help to rule out
effects of a patient’s genetic background on disease outcome. Weaker but still valuable
support can be provided by assays performed in model organisms, more artificial cell culture
systems, and non-cellular models such as construct-based assays of altered protein–protein
interactions or transcript splicing. Models are most valuable if they directly mimic the
predicted functional impact of the candidate variants: for example, knockout mice are better
models of recessive loss of function than of dominant missense mutations in a candidate
gene. In the case of compound heterozygous recessive inheritance—particularly if the
proposed mode of action depends on an interaction between allelic variants, such as in TAR
(thrombocytopenia with absent radius) syndrome30—it will be necessary to develop cellular
assays that incorporate and assess multiple variants simultaneously.
The impact of variation in non-protein-coding regions of the genome—such as splicing and
transcriptional enhancers—remains particularly challenging to interpret, but we note that
systematic experimental approaches have begun to both highlight the regions of the human
genome most likely to have a role in gene regulation46, and to dissect the potential impact of
variation within them47. However, given the challenges of predicting impact for non-coding
variants, it remains critical to determine whether the purported pathogenic variant does in
fact produce the expected effect on expression or splicing of the affected gene, either by
demonstrating an unusual expression level in the patient or by in vitro experimentation (such
as minigene constructs).
We caution against the assumption that convincingly implicated variants, even in presumed
monogenic disorders, are necessarily fully penetrant (that is, sufficient in isolation to cause
disease). In fact the penetrance of most reported disease-associated mutations has not been
accurately assessed with current data owing to the biases associated with sample
ascertainment. Indeed, the prevalence of reported severe-disease-causing mutations in
population controls2,3 suggests that incomplete penetrance, false assignment of
pathogenicity, or wider-than-appreciated ranges of expressivity are a substantially more
common feature of reported Mendelian disease mutations than generally appreciated.
Accurate estimates of penetrance require characterization of reported mutations in large,
well-phenotyped population cohorts48–50. Further large-scale studies of this kind should be a
priority for the field.
We also note the underappreciated importance of calibrating the accuracy of functional
assays by large-scale testing of variants confidently established to be non-pathogenic (for
example, common missense polymorphisms in the gene of interest). Such experiments
establish a baseline estimate for the impact of well-tolerated variants on the assay in
question.
Publication and data sharing
As noted above, there are many false positives in disease-mutation databases, stemming
largely from erroneous assignment of pathogenicity both in clinical diagnostic laboratories
and in the primary literature1,2,51. To reduce this burden will require robust, centralized
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trepositories of mutation data, incorporating explicit, structured evidence for variant
pathogenicity and systems for rapid correction of entries. To incentivize both research and
clinical laboratories to deposit variation data into open repositories, and to update evidence
for or against implication, is a key challenge to be addressed by funding bodies, journals,
research consortia, clinical organizations and others52. We are hopeful that such activities
can be coordinated around the US National Center for Biotechnology Information (NCBI)’s
newly launched ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/), which will also
interface with existing efforts in this space including the LOVD (Leiden Open (source)
Variation Database)53 and other locus-specific databases, OMIM (Online Mendelian
Inheritance in Man; http://omim.org/) and DECIPHER (Database of Chromosomal
Imbalance and Phenotype in Humans Using Ensembl Resources)54.
In some cases—such as diseases that are extremely rare or have high degrees of locus
heterogeneity—it may be impossible to obtain definitive evidence implicating a specific
gene or variant with available sample sizes. In such cases we acknowledge that the
suggestive evidence pointing to a gene’s potential implication can nevertheless be valuable
in future clinical and research investigations, and should not be excluded from publications
or the public domain. However, it is incumbent on investigators, reviewers and journals to
be explicit in describing the supporting evidence and the degree of confidence in causality
for each proposed gene association and reported variant.
Finally, we emphasize the value of sharing sequence and phenotype data from clinical and
research samples to the fullest possible extent. Many investigators and research funders
consider responsible data sharing to be a moral and professional imperative55. In many
cases, particularly for extremely rare phenotypes, individual laboratories that are not actively
recruiting subjects will evaluate only a handful of samples. Sharing of sequence data among
testing laboratories has often been restricted, so that many potentially pathogenic mutations
and associated phenotypes are known only to individual laboratories. The availability of
genome-wide variant calls and detailed clinical phenotype descriptions from such patients in
centralized repositories—which will require substantial investment both in informatic
infrastructure and new ethical frameworks—would permit more rapid accumulation of
evidence for novel genes, and continuous reanalysis to refine the classification of potentially
implicated variants and the genotype–phenotype map of human disease. Models for
successful data sharing efforts in rare disease already exist in the field of copy number
variation with the DECIPHER database54 and the International Standards for Cytogenomic
Arrays Consortium (https://www.iscaconsortium.org/), aided by an increasing number of
rare-disease resource consortia, and several ambitious efforts to establish clear global
standards for genomic data sharing are now underway56.
Added challenges in clinical settings
Although this summary is focused on research, research findings provide the foundation for
clinical interpretation. Questionable attributions of causality based on weak research
evidence can be readily propagated through research databases and can be misinterpreted
clinically as stronger than they truly are. Thus, even researchers who do not explicitly
MacArthur et al. Page 11
Nature. Author manuscript; available in PMC 2014 October 24.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tprovide diagnosis to patients should be aware that their published findings may be used as
support for decisions made in clinical settings.
Clinical laboratories face similar challenges in assessing variant pathogenicity as do
researchers, but with the added pressures of diagnostic urgency and the potentially severe
consequences of misdiagnosis. Although guidelines are available for variant interpretation in
a diagnostic setting57, analytical frameworks for next-generation sequencing data are only
beginning to emerge58,59. Responsible application of these technologies will require
standards for test validation, variant interpretation and return of results.
The results of genetic and genomic testing are increasingly being used in medical decision-
making, including recommendations for prophylactic mastectomy, cardiac defibrillator
implantation, tumour therapy and prenatal diagnosis. These actions are neither generally
inappropriate nor uniformly incorrect; however, the potential for harm due to
misinterpretation of variants is substantial. Although physicians must often make medical
decisions using imperfect or ambiguous data, it is critical that healthcare providers be made
aware of the varying levels of certainty in the evidence for implicating a variant in disease,
both through the consistent use of variant classification terminologies and descriptions of the
supporting evidence or lack thereof.
Conclusions
High-throughput DNA sequencing technologies provide unprecedented opportunities to
discover new genes and variants underlying human disease, but these discoveries must be
rigorously performed and replicated to prevent the proliferation of false-positive findings.
Assessment of evidence for variant implication is a two-step process. First, the overall
evidence for implication of a gene should be considered, focusing primarily on the statistical
support for implication from genetic analyses, potentially supplemented by ancillary data
from informatic sources and functional studies. Second, a combined assessment of the
genetic, experimental and informatic support for individual candidate variants should be
performed. Such assessments should be performed even if the genes or variants have been
previously reported as confidently implicated; prior evidence should be continuously re-
evaluated with newly available information.
We urge that, whenever possible, investigators assess the results of genetic, informatic and
functional analyses within a quantitative statistical framework, such as determining the
probability of the observed distribution of genetic variants in cases and controls under the
null hypothesis, and the a priori power to detect variants of a specified frequency and effect
size. The specificity of experimental or informatic results provided in support of implication
should also be assessed whenever possible by asking how often a similar result would be
obtained by chance among a set of random variants or genes. In such analyses investigators
should take advantage of the increasing availability of genome-scale sequencing and
functional data, and help to build these resources by contributing their findings to public
databases.
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areas (Box 2). In particular, major improvements in databases of reported pathogenic
mutations, including details of the evidence supporting pathogenicity, are urgently needed.
Large-scale experiments to assay previously reported disease-associated mutations in
additional large, well-phenotyped populations will also be required to confirm pathogenicity
and provide robust evidence of penetrance and expressivity. Finally, extensive work is
needed to develop formal statistical frameworks for quantifying the strength of the evidence
for implication.
Objective, systematic and quantitative evaluation of the evidence for pathogenicity and
sharing of these evaluations and data amongst research and clinical laboratories will
maximize the chances that disease-causing genetic variants are correctly differentiated from
the many rare non-pathogenic variants seen in all human genomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tBox 1 | Definitions of terms used to describe sequence variants
Lack of clarity in the terms used to describe sequence variants is a major source of
confusion in human genetics. We have adopted the following definitions for terms used
throughout this manuscript:
Pathogenic: contributes mechanistically to disease, but is not necessarily fully penetrant
(i.e., may not be sufficient in isolation to cause disease).
Implicated: possesses evidence consistent with a pathogenic role, with a defined level of
confidence.
Associated: significantly enriched in disease cases compared to matched controls.
Damaging: alters the normal levels or biochemical function of a gene or gene product.
Deleterious: reduces the reproductive fitness of carriers, and would thus be targeted by
purifying natural selection.
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tBox 2 | Guidelines for implicating sequence variants in human disease
General guidelines
• Provide complete positive and negative evidence associated with the gene or
variant implication, not just the results that are consistent with pathogenicity.
• In all cases in which it is possible, place genetic, informatic and experimental
results within a quantitative framework: determine the probability of observing
this result by chance with a randomly selected variant or gene.
• Take advantage of public data sets of genomic variation, functional genomic
data and model-organism phenotypes.
• Do not regard prior reports of gene or variant implication as definitive: to the
degree that supporting data are available, reassess them as rigorously as your
own data.
• Describe and assess clearly the available evidence supporting prior reports of
gene or variant implication.
Assessment of evidence for candidate disease genes
• In presumed monogenic-disease cases, evaluate genes previously implicated in
similar phenotypes before exploring potential new genes.
• Report a new gene as confidently implicated only when variants in the same
gene and similar clinical presentations have been confidently implicated in
multiple unrelated individuals.
• In all cases in which it is possible, apply statistical methods to compare the
distribution of variants in patients with large matched control cohorts or well-
calibrated null models.
Assessment of evidence for candidate pathogenic variants
• Determine and report the formal statistical evidence for segregation or
association of each variant, and its frequency in large control populations
matched as closely as possible to patients in terms of ancestry.
• Recognize that strong evidence that a variant is deleterious (in an evolutionary
sense) and/or damaging (to gene function) is not sufficient to implicate a variant
as playing a causal role in disease.
• Predict variant deleteriousness with comparative genomic approaches, but avoid
considering any single method as definitive or multiple methods as independent
lines of evidence for implication.
• Validate experimentally the predicted damaging impact of candidate variants
using assays of patient-derived tissue or well-established cell or animal models
of gene function.
• Avoid assuming that implicated variants are fully penetrant, or completely
explanatory in any specific disease case.
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tPublications and reporting
• Assess and report objectively the overall strength and cohesiveness of the
evidence supporting pathogenicity for all variants listed in a publication.
• In all cases in which it is possible, ensure that the level of confidence of
pathogenicity and supporting evidence are propagated in variant databases.
• Deposit genotype and phenotype data for both controls and disease patients, and
for resultant analyses demonstrating associations, in publicly accessible
databases, to the maximum degree permissible under study-specific participant
consent and ethical approval.
• If returning results for clinical use, highlight strong, actionable findings but also
ensure that uncertain or ambiguous findings are clearly conveyed as such, along
with appropriate supporting evidence.
• Provide clear cautions regarding decision-making based on variants with limited
evidence when the potential for use in medical interventions is high.
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tBox 2 | Priorities for research and infrastructure development
• Improved public databases of human genetic variants incorporating explicit, up-
to-date supporting evidence for variant implication in disease and audit trails
recording changes in interpretation.
• Improved incentives, and ethical and logistical solutions, for sharing of genetic
and phenotypic data from both research and clinical diagnostic laboratories.
• Public databases of variant and allele frequency data from large sets of
population reference samples from a wide range of ancestries.
• Large-scale genotyping of reported human disease-causing variants in large,
well-phenotyped population cohorts, reducing biases in the assessment of the
associated penetrance and phenotypic heterogeneity.
• Development and benchmarking of standardized, quantitative statistical
approaches for objectively assigning probability of causation to new candidate
disease genes and variants.
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Table 1
Classes of evidence relevant to the implication of sequence variants in disease
Evidence
level
Evidence
class
Examples
Gene level Genetic Gene burden: the affected gene shows statistical excess of rare (or de novo) probably damaging variants
segregating in cases compared to control cohorts or null models.
Experimental Protein interactions: the gene product interacts with proteins previously implicated (genetically or
biochemically) in the disease of interest.
Biochemical function: the gene product performs a biochemical function shared with other known genes in
the disease of interest, or consistent with the phenotype.
Expression: the gene is expressed in tissues relevant to the disease of interest and/or is altered in expression in
patients who have the disease.
Gene disruption: the gene and/or gene product function is demonstrably altered in patients carrying candidate
mutations.
Model systems: non-human animal or cell-culture models with a similarly disrupted copy of the affected gene
show a phenotype consistent with human disease state.
Rescue: the cellular phenotype in patient-derived cells or engineered equivalents can be rescued by addition of
the wild-type gene product.
Variant level Genetic Association: the variant is significantly enriched in cases compared to controls.
Segregation: the variant is co-inherited with disease status within affected families and additional co-
segregating pathogenic variants are unlikely or have been excluded.
Population frequency: the variant is found at a low frequency, consistent with the proposed inheritance model
and disease prevalence, in large population cohorts with similar ancestry to patients.
Informatic Conservation: the site of the variant displays evolutionary conservation consistent with deleterious effects of
sequence changes at that location.
Predicted effect on function: variant is found at the location within the protein predicted to cause functional
disruption (for example, enzyme active site, protein-binding region).
Experimental Gene disruption: the variant significantly alters levels, splicing or normal biochemical function of the product
of the affected gene. This is shown either in patient cells or a well-validated in vitro model system.
Phenotype recapitulation: introduction of the variant, or an engineered gene product carrying the variant, into
a cell line or animal model results in a phenotype that is consistent with the disease and that is unlikely to
arise from disruption of genes selected at random.
Rescue: the cellular phenotype in patient-derived cells, model organisms, or engineered equivalents can be
rescued by addition of wild-type gene product or specific knockdown of the variant allele.
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